Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye PART 2 (OD)

Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 2 (MD)

EPISODE 5 : Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye (PART 2) Preeya Gupta, MD & Christopher Starr, MD, FACS With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Christopher Starr, MD, joins Preeya Gupta, MD, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 1 (MD)

EPISODE 5 : Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye (PART 1) Preeya Gupta, MD & Christopher Starr, MD, FACS With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Christopher Starr, MD, joins Preeya Gupta, MD, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye PART 2 (OD)

Episode 5 - Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 2 (OD) Walt Whitley, OD, MBA, FAAO, & Marc Bloomenstein, OD, FAAO With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Dr. Marc Bloomenstein, OD, FAAO joins Walt Whitley, OD, MBA, FAAO, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye PART 1 (OD)

Episode 5 - Stepping Boldly Forward with Short-Term Rx Treatment for Dry Eye Part 1 (OD) Walt Whitley, OD, MBA, FAAO, & Marc Bloomenstein, OD, FAAO With a burgeoning influx of Dry Eye patients coming in daily to practices, there is a need to embrace the prevalence and natural history of Dry Eye Flares—or an acute worsening of symptoms. This is a critical first step when identifying the type of Dry Eye patient, whether for acute or chronic care management. In this podcast, Dr. Marc Bloomenstein, OD, FAAO joins Walt Whitley, OD, MBA, FAAO, to discuss the potential benefits of EYSUVIS® as a short-term Rx treatment for Dry Eye, the IOP safety profile, and the importance of patient empowerment when initiating therapy for Dry Eye Flares.

Thinking Differently: An In-Depth Look at Dry Eye Flares (MD)

EPISODE 4: Thinking Differently: An In-Depth Look at Dry Eye Flares Preeya Gupta, MD, & Sarah Darbandi, MD Most of us, including many clinicians, can get lost in the forest for the trees when trying to understand Dry Eye and Dry Eye Flares. With up to 70-80% of Dry Eye patients in some practices suffering from Dry Eye Flares, it’s important for practitioners to understand where these numbers are coming from, and what they can do to lower them. In this podcast, Dr. Sarah Darbandi, MD, joins Preeya Gupta, MD, to discuss the importance of communication surrounding triggers and treatment options with patients, as well as keeping practitioners up-to-date with the current literature to better understand the pathophysiology of the condition.